Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Chemotherapy (Florence, Italy)
|
May 8, 2015
Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Oktay Bozkurt, Halit Karaca, Ilhan Hacıbekiroglu, et al.
Oncology Letters
|
October 19, 2013
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
Umut Kefeli, Mustafa Benekli, Alper Sevinc, et al.
Hepato-Gastroenterology
|
November 21, 2012
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience
Umut Kefeli, Suleyman Buyuberber, Murat Akyol, et al.
Contemporary Oncology (Poznan, Poland)
|
September 27, 2014
Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology
Kucukoner Mehmet, Cihan Sener, Ummugul Uyeturk, et al.
Cancers
|
November 27, 2024
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes
Mehmet Fatih Ozbay, Hakan Harputluoglu, Mustafa Karaca, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
American Journal of Cancer Research
|
February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights
Aysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Journal of Cancer Research and Clinical Oncology
|
April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Scientific Reports
|
March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Chemotherapy (Florence, Italy)
|
May 8, 2015
Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Oktay Bozkurt, Halit Karaca, Ilhan Hacıbekiroglu, et al.
Oncology Letters
|
October 19, 2013
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
Umut Kefeli, Mustafa Benekli, Alper Sevinc, et al.
Hepato-Gastroenterology
|
November 21, 2012
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience
Umut Kefeli, Suleyman Buyuberber, Murat Akyol, et al.
Contemporary Oncology (Poznan, Poland)
|
September 27, 2014
Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology
Kucukoner Mehmet, Cihan Sener, Ummugul Uyeturk, et al.
Cancers
|
November 27, 2024
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes
Mehmet Fatih Ozbay, Hakan Harputluoglu, Mustafa Karaca, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
American Journal of Cancer Research
|
February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights
Aysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
Cancer Investigation
|
December 13, 2021
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, et al.
Journal of Cancer Research and Clinical Oncology
|
April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Scientific Reports
|
March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Page
of 3